More Good News For Bayer's Larotrectinib Ahead Of FDA Verdict

23 Oct 2018

An update on Bayer and Loxo's tissue-agnostic therapy for cancers with NTRK gene fusions has impressed, confirming the sustained durable effect of larotrectinib as it nears its action date for approval in the US.

Runner — Larotrectinib data driving drug to approval line • Source: Shutterstock

Updates on the tissue-agnostic drug larotrectinib presented at ESMO have confirmed that Bayer AG and Loxo Oncology Inc.'s tropomyosin receptor kinase inhibitor, which could be approved by the FDA in the next month, showed robust activity across different tumor types, consolidating its lead over Roche's rival therapy entrectinib.

Having reported impressive Phase III data at ASCO in 2017 on 55 patients, the companies presented updated results on larotrectinib at the Munich congress on those patients and an additional 67 adults and children suffering

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

15 May 2025

• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

China Biopharma Podcast

14 May 2025

• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

13 May 2025

• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

13 May 2025

• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.